Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | G. Garcia-Manero | J. Cortes | Xuelin Huang | F. Ravandi | E. Jabbour | N. Daver | C. Dinardo | S. O'brien | J. Khoury | N. Pemmaraju | N. Jain | N. Short | J. Jorgensen | W. Wierda | K. Sasaki | R. Garris | J. Alvarez | Rebecca E. Garris